Award Number: DAMD17-00-1-0719

TITLE: Hepatitis C Virus Infection: Mechanisms of Disease Progression

PRINCIPAL INVESTIGATOR: COL Maria Sjogren
Brooke M. Huntley

CONTRACTING ORGANIZATION: TRUE Research Foundation
San Antonio, TX 78217

REPORT DATE: October 2005

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and
should not be construed as an official Department of the Army position, policy or decision
unless so designated by other documentation.
An estimated 4 million individuals in the USA are chronically infected with the hepatitis C virus. Annually, 8,000 to 10,000 of these subjects will die of liver-related complications and approximately 1,000 will require liver transplantation. The United States military have rates of HCV infection similar to the general US population (1.6%). However, it is a younger population and its natural history of HCV infection has not been studied. Therefore, the clinical outcome of HCV-infected military subjects and risk factors contributing to disease progression are largely unknown. Such knowledge is essential for decisions regarding optimal management and prevention of the disease. This study focuses on active duty military subjects infected with HCV, who will be enrolled and observed prospectively over four years (48 months). Liver biopsies are to be performed at initiation if needed and at completion of study to observe for disease progression. Lab evaluation of virologic and biochemical indicators of the disease and detailed information about risk factors, and quality of life are collected by questionnaire every six months. Currently, 90 subjects have been enrolled and 77 subjects are being followed. It is too early to analyze the data in terms of disease progression and potential contributing factors to disease progression specific to this population, as only 3 subjects have completed the study. Therefore, the data presented in this report will be confined to descriptive statistics of the sample to date.
# Table of Contents

Cover

SF 298

Introduction

Body

Key Research Accomplishments

Reportable Outcomes

Conclusions

References

Appendices
INTRODUCTION

An estimated 4 million individuals in the USA are chronically infected with the Hepatitis C virus. Annually, 8,000 to 10,000 of these people will die of liver related complications and approximately 20,000 are waitlisted for liver transplantation with 20% actually receiving a new liver. Thus, HCV is a major public health problem. The US military population has rates of HCV infection similar to the general US population with an overall rate of 1.6%. However, it is a younger population and the natural history of HCV infection in the population has not been studied. Therefore, the clinical outcome of HCV infected military subjects is largely unknown. Specific factors in military life have not been studied to observe if they contribute to disease progression. Such knowledge is essential for decisions regarding optimal prevention and management of the disease.

Active duty service members with chronic HCV infection will be enrolled and observed prospectively over four years in this study. Our principal hypothesis is that in active duty members infected with HCV genotype-1, liver disease progresses more rapidly than in subjects infected with HCV non-genotype-1. The effect of other factors that might influence histologic progression of liver disease including age, race, rank, deployment, alcohol consumption, and HCV RNA level will be assessed. To test this hypothesis we have the following specific aims:

- To compare the rate of progression of liver disease based on a histologic severity scale in military subjects infected with genotype-1 to the rate of progression in those infected with non-genotype-1.
- To identify other predictors of progression of histologic liver disease in a military population.
- To determine risk factors for acquisition of genotype-1 compared to non-genotype-1 HCV.
- To describe the natural history of HCV infection in a group of a military population.

BODY

To date approximately 285 patients have been approached about participation in the study, with approximately 35 patients having been contacted in the last year. Of those contacted, 90 subjects have been successfully enrolled. There are 77 active participants (participants currently being followed) ranging in status from baseline to month 42. Additionally, 3 subjects have completed the study with all completing at least eight of nine visits. In addition, to the 80 active or finished participants, 2 are deceased, 3 withdrew consent and 5 have been unable to be contacted for over 1 year and have subsequently been dropped from the study. (see figure 1) Of those who terminated early, reasons cited included too far to travel and one felt the questions were not relevant, the others were lost to follow up. Enrollment is open and ongoing. We hope to accrue between 86-120 patients total. This goal required downward adjusting in part due to the loss of Balboa Medical Center as an expected participating site. Deployment of active duty to Iraq, Afghanistan, etc. since 2002, as well as staff turnover due to relocation and deployment to Iraq in the WRAMC Center for Liver Disease within the past year has unfortunately created eligible potential subjects being overlooked.

Figure 1.
Because of enrollment below our expected subject participation, a previous review had requested that we conduct a sample size analysis to determine the minimum number of subjects in the study to be able to conduct valid statistical analysis. The number of subjects varies between 120 and 160 depending on the difference of study characteristics in the studied groups (genotype 1 vs. non-1, officer vs. enlisted, cirrhosis vs. non-cirrhosis, etc). However, if the difference was striking (in the order of 25% to 30%), a sample size of 43 subjects per group would be enough, we plan to finish enrollment in October 2006, we asked our NNMC colleagues to send eligible subjects to our Liver Clinic to increase our ‘n’ to our goal of 120 subjects. A no cost extension will be requested to improve our enrollment figures.

This is not an interventional study, no adverse events have been reported since the last APR.

At this point, 3 subjects have completed the study. Due to this number being so small, inferences cannot be made about histological progression until there is complete study data including the second liver biopsy for a greater number of subjects. However, the existing active sample including the 3 completed patients can be described as follows:

**Sample Demographics:**
- 82% of the sample is male.
- The current ages of the subjects range from 22 to 59. The mean age is 44.
- 22% of the sample is African American. 60% are Caucasian, 10% are Latino, 5% are Asian, and 3% are of unknown ethnicity (see figure 2).

**Baseline Lab/Histology Data:**
- By and large the sample does not have indicators of advanced (decompensated) liver disease as evidenced by biochemical indicators. At baseline, the mean PT is 13.54, mean albumin is 4.08, and mean ALT is 99.92.
- 41.8% of the sample had ALT less than 72, which is the high limit for males at WRAMC laboratories.
- 77.4% of the sample is genotype-1, 21.4% is genotype-non-1, and 1.2% of the sample is unknown.
- 62.8% of the sample had viral loads >500,000 IU/mL. Of the total sample, 14.0% had viral loads >850,000 IU/mL.
- 24.3% of the sample had no or minimal fibrosis. 31.1% of the sample showed signs of periportal fibrosis and 29.7% of the sample had bridging fibrosis. 6% of the sample had cirrhosis.

![Race Demographics of Active Participants](image_url)
Lifestyle Factors potentially contributing to disease acquisition or progression:
- 12.7% of the sample self reports having a drinking problem now or in the past.
- 10.1% has had a DUI.
- 26.7% of the sample have answered one of the CAGE questions affirmatively.
- 64.6% of the sample has a tobacco use history, but only 25.3% are current smokers.
- 13.9% had been incarcerated.
- 38% of the sample has had more than 10 sexual partners.
- 17.7% has had sexual intercourse with a prostitute.

Risk Factor Analysis (see figure 3):
- 20% of the sample has a prior history of blood transfusion.
- 45.6% has at least one body piercing.
- 45% of the sample is tattooed.
- 13.8% has had acupuncture.
- 5% has had needle sticks.
- 35% has been in combat.
- 7.6% of the sample has a past history of IV Drug Use.
- 61.8% report having had cutaneous exposure to somebody else’s blood.
- 63.6% shared nail trimming instruments.

Figure 3.

<table>
<thead>
<tr>
<th>Percentage of Risk Factor Exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood Transfusion</td>
</tr>
<tr>
<td>Body Piercing</td>
</tr>
<tr>
<td>Tattooed</td>
</tr>
<tr>
<td>Acupuncture</td>
</tr>
<tr>
<td>Needle Sticks</td>
</tr>
<tr>
<td>Combat</td>
</tr>
<tr>
<td>IV Drug Use</td>
</tr>
<tr>
<td>Exposure to Blood</td>
</tr>
</tbody>
</table>

We were able to examine this preliminary data to see if any trends or patterns emerged, specifically with respect to our aim of determining if there were any specific risk factors for acquisition of genotype-1 compared to non-genotype-1 HCV (see tables 1 and 2). Although not significant, trends emerged suggesting, in general, genotype-1 infected individuals may be more likely to have lifestyle risk factors whereas, genotype non-1 may be more likely to have other risk factors.

Table 1.

<table>
<thead>
<tr>
<th>Lifestyle Risk Factors</th>
<th>Incarceration</th>
<th>IV Drug Use</th>
<th>Drinking Problem</th>
<th>DUI</th>
<th>Sex with &gt;10 Partners</th>
<th>Sex w/a Prostitute</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype-1</td>
<td>10.2%*</td>
<td>7.5%</td>
<td>10.2%</td>
<td>11.9%</td>
<td>35.6%</td>
<td>20.3%</td>
</tr>
<tr>
<td>Genotype Non-1</td>
<td>22.2%**</td>
<td>5.6%</td>
<td>17.7%</td>
<td>5.6%</td>
<td>44.4%</td>
<td>5.8%</td>
</tr>
</tbody>
</table>

*83.3% (<1 year); 16.7% (3-5 years)
**100% (<1 year)
Table 2.

<table>
<thead>
<tr>
<th>Other Risk Factors</th>
<th>Transfusion</th>
<th>Acupuncture</th>
<th>Tattoo</th>
<th>Piercing</th>
<th>Exposure to Blood</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype-1</td>
<td>20.3%</td>
<td>11.9%</td>
<td>40.7%</td>
<td>45.8%</td>
<td>59.3%</td>
</tr>
<tr>
<td>Genotype Non-1</td>
<td>22.2%</td>
<td>16.7%</td>
<td>55.6%</td>
<td>49.7%</td>
<td>67.7%</td>
</tr>
</tbody>
</table>

Looking at the relationship between genotype and demographics revealed that 61.9% of officers were genotype-1 while 83.1% of the enlisted subjects were genotype-1 (see figure 4). This difference was not significant.

Figure 4.

Quality of Life:
- 21.7% of the sample feels that they have been limited by their HCV in the past two weeks in performing their daily work at least some of the time during the past two weeks.
- 20.3% of the sample feels that their HCV has limited their activities (walking, climbing, stairs, carrying groceries, playing sports) at least some of the time in the past two weeks.
- 37.7% of the sample has had difficulty sleeping at night at least some of the time during the last two weeks.
- 30.4% of the sample worried at least some of the time during the past two weeks that their symptoms will develop into major problems.
- 26.1% of the sample worried at least some of the time during the past two weeks that they might die earlier than expected because of their Hepatitis C.
- 21.7% of the sample experienced emotional stress or strain in their relationships at least some of the time during the past two weeks as a result of their hepatitis C.

These data are generated from the chronic liver disease questionnaire-HCV (CLDQ-HCV), which is asked at baseline and each patient visit. The above results express how subjects (n=90) felt at their most recent visit. An additional Quality of Life questionnaire, the SF-36 of Hepatitis Quality of Life Questionnaire (HQLQ), is also administered at each visit. Upon completion of the study, HQLQ data will be scored by a professional scoring service, therefore, no analysis is available at the time of this report.

Therapy Outcomes
Although the subjects enrolled in this study do not receive any anti viral therapy as a part of the study, a number of subjects are have been enrolled in other studies involving treatment and/or have received such treatment at the WRAMC Liver Clinic. The below statistics were calculated for the 90 patients that were enrolled for the study.
- 56% (n=50) of the sample has been exposed to an Interferon treatment while participating in this study.
- Of those exposed to Interferon treatment, currently,
72\% (n=36) are currently showing a viral response or have a sustained viral response to the treatment and currently have undetectable HCV viral loads.

2\% (n=1) relapsed after showing initial response to the treatment.

**KEY RESEARCH ACCOMPLISHMENTS**

Enrolled 90 subjects.

**REPORTABLE OUTCOMES**

None at this time.

**CONCLUSIONS**

Inferences cannot be made about histological progression of hepatitis C in this population as there have only been three subjects that have completed the study. Until there are more patients with complete study data including the second liver biopsy conclusions are unavailable. However, interesting trends are beginning to emerge with respect to genotype, military rank, and risk factors. As more data is obtained, analysis that looks at the other indicators of disease progression such as biochemical markers will also be able to be performed. Additionally, it is hoped that the morbidity and quality of life data will lend insight into an under-researched area of study in this disease process in the active duty military population.

**REFERENCES**

None at this time.

**APPENDICES**

Not applicable.